IDWeek: Annual Meeting 2025 Highlights
Description
IDWeek: Annual Meeting 2025 Highlights
Summary
IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.
IDWeek 2025 took place in Atlanta, Georgia, between 19-22 October 2025.
GlobalData's infectious diseases team attended industry-sponsored and scientific sessions where key therapies were featured, the contents of which were analyzed to create this IDWeek 2025 Highlights report.
Scope
Indications, companies, and therapies discussed in the report are as follows -
This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as HIV, COVID-19, RSV, NTM, UTIs, and more.
Inside the report you’ll find -
Summary
IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.
IDWeek 2025 took place in Atlanta, Georgia, between 19-22 October 2025.
GlobalData's infectious diseases team attended industry-sponsored and scientific sessions where key therapies were featured, the contents of which were analyzed to create this IDWeek 2025 Highlights report.
Scope
Indications, companies, and therapies discussed in the report are as follows -
- Respiratory syncytial virus (RSV)
- Moderna - mRNA-1345 (mRESVIA)
- Enanta Pharmaceuticals - EDP-323
- COVID-19
- Moderna - mRNA-1273.815 (Spikevax XBB.1.5)
- Invivyd - Pemivibart (Pemgarda)
- Complicated urinary tract infections (cUTIs)/acute pyelonephritis
- GSK and Spero Therapeutics - Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr)
- HIV
- ST Pharm - Pirmitegravir (STP0404)
- Nontuberculous mycobacteria (NTM)
- Paratek Pharmaceuticals - Omadacycline (Nuzyra)
- Gonorrhea
- Innoviva Specialty Therapeutics - Zoliflodacin
- Complicated Staphylococcus aureus bacteremia (SAB)
- Armata Pharmaceuticals - AP-SA02
- Fungal Infections
- Elion Therapeutics - EL219
- Herpes simplex virus (HSV)
- AiCuris - Pritelivir
This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as HIV, COVID-19, RSV, NTM, UTIs, and more.
Inside the report you’ll find -
- Emerging trends in prophylactic or therapeutic strategies for the management of viral, bacterial, and fungal infections
- Insights into the disease areas that took precedence at the conference
- Key takeaways from headline sessions and late-breaking data
- Clinical and commercial implications of notable presentations
Table of Contents
- 1. Key Takeaways
- 2. AME in Global Context
- 3. Competitive Dynamics
- 4. Mobile Broadband Subscription Trends
- 5. Mobile Broadband Revenue Trends
- 6. Key Takeaways and Recommendations
- 7. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
